Gilead Sciences, Inc. (NASDAQ:GILD) Director John Francis Cogan sold 2,700 shares of the business’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $65.07, for a total value of $175,689.00. Following the completion of the transaction, the director now directly owns 57,560 shares in the company, valued at approximately $3,745,429.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of GILD traded up $0.32 during trading hours on Thursday, hitting $64.92. 9,067,789 shares of the stock traded hands, compared to its average volume of 7,645,234. The company has a quick ratio of 3.30, a current ratio of 3.38 and a debt-to-equity ratio of 1.19. Gilead Sciences, Inc. has a 1-year low of $60.32 and a 1-year high of $79.61. The firm has a market capitalization of $82.40 billion, a PE ratio of 10.56, a price-to-earnings-growth ratio of 4.12 and a beta of 1.16.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, missing the consensus estimate of $1.70 by ($0.26). Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.52 billion. During the same period in the previous year, the company posted $1.78 EPS. The company’s quarterly revenue was down 2.6% compared to the same quarter last year. Analysts anticipate that Gilead Sciences, Inc. will post 6.23 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 28th. Shareholders of record on Friday, March 15th will be paid a $0.63 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.57. The ex-dividend date is Thursday, March 14th. This represents a $2.52 annualized dividend and a yield of 3.88%. Gilead Sciences’s dividend payout ratio is presently 40.98%.
Large investors have recently added to or reduced their stakes in the business. S&CO Inc. lifted its stake in Gilead Sciences by 5.5% in the fourth quarter. S&CO Inc. now owns 6,325 shares of the biopharmaceutical company’s stock valued at $396,000 after buying an additional 330 shares during the period. Addenda Capital Inc. increased its holdings in shares of Gilead Sciences by 2.3% in the fourth quarter. Addenda Capital Inc. now owns 59,731 shares of the biopharmaceutical company’s stock worth $3,735,000 after acquiring an additional 1,362 shares in the last quarter. IMA Wealth Inc. increased its holdings in shares of Gilead Sciences by 31.6% in the fourth quarter. IMA Wealth Inc. now owns 7,121 shares of the biopharmaceutical company’s stock worth $445,000 after acquiring an additional 1,710 shares in the last quarter. Clear Perspective Advisors LLC increased its holdings in shares of Gilead Sciences by 3.6% in the fourth quarter. Clear Perspective Advisors LLC now owns 8,680 shares of the biopharmaceutical company’s stock worth $543,000 after acquiring an additional 300 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of Gilead Sciences by 199,789.8% in the third quarter. Bank of New York Mellon Corp now owns 31,350,714 shares of the biopharmaceutical company’s stock worth $2,420,587,000 after acquiring an additional 31,335,030 shares in the last quarter. 79.13% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts have commented on GILD shares. Citigroup reissued a “buy” rating and issued a $100.00 price objective on shares of Gilead Sciences in a research note on Tuesday, February 5th. Guggenheim began coverage on Gilead Sciences in a research note on Monday, December 17th. They set a “buy” rating and a $86.00 price target on the stock. BidaskClub raised Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Tuesday, December 4th. Raymond James set a $94.00 price target on Gilead Sciences and gave the company a “buy” rating in a research note on Thursday, December 20th. Finally, Maxim Group set a $84.00 price target on Gilead Sciences and gave the company a “buy” rating in a research note on Tuesday, February 5th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. Gilead Sciences has a consensus rating of “Hold” and a consensus price target of $82.29.
ILLEGAL ACTIVITY NOTICE: “Insider Selling: Gilead Sciences, Inc. (GILD) Director Sells 2,700 Shares of Stock” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2019/03/21/insider-selling-gilead-sciences-inc-gild-director-sells-2700-shares-of-stock.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
Further Reading: Why is a lock-up period needed for an IPO?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.